| Abstrakt: |
A recent study conducted by researchers at the University of Florence in Italy explored the potential benefits of a compound containing gamma-aminobutyric acid (GABA) and Melissa officinalis (Mo) on post-inflammatory irritable bowel syndrome (IBS). The study found that the compound, known as GABA-Mo, was effective in reducing visceral pain and intestinal inflammation in rats with colitis. It also improved intestinal barrier integrity and promoted healing from colon damage. These findings suggest that GABA-Mo could be a promising approach for managing abdominal pain, particularly in the remission stages of colitis. [Extracted from the article] |
